FY results from Horizon Discovery are in line with the performance and trends set out in the company’s pre-close statement on 18th January. As expected and previously confirmed the Products division (mainly X-MANTM cell lines and reagents) performed particularly strongly over the period. We note the strong YTD share price performance (+32%) and reiterate our Buy recommendation.
